A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

Southern Illinois Healthcare Foundation

Status: Completed

Conditions: HIV-1-infection

Treatments: Drug: Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03198884

16-1108-100C

Details and patient eligibility

About

A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥18 years old
• Received a regimen of darunavir 800 mg/ritonavir 100 mg in combination with dolutegravir 50 mg QD for ≥24 weeks as documented in EMR
• Laboratory reports (CD4, viral load, SrCr) available at time points +/- 4 6 weeks from 12, 24, 36, 48 weeks from start of regimen
• Resistance data (if applicable)

Exclusion criteria

• Received a regimen of darunavir/ritonavir in combination with dolutegravir for <24 weeks duration
• Patients receiving darunavir/ritonavir + DTG+NRTI's
• Missing laboratory data in ≥2 study time points
• Patients missing more than five doses over two weeks prior study visit

Trial design